Several pharmaceutical companies, including Bayer, Eisai, Gilead, MSD, Novo Nordisk and Sanofi, have backed warnings from the Association of the British Pharmaceutical Industry that the £3.3bn “extreme revenue clawback” companies will have to pay the government in 2023 means they will invest less in the UK and launch fewer new products there.
The companies also supported the ABPI’s call for "early and open" talks with the government next year over the soaring rebate rate, which will cost companies selling branded medicines 26.5% of their annual sales
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?